Christophe Massard

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Peter H. O’Donnell, Christophe Massard et al. · JAMA Oncology · 2017 · 846 citations

Medicine, Oncology, Pharmacotherapy +17

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma et al. · Journal of Clinical Oncology · 2016 · 845 citations · Full text

Medicine, Oncology, Urology +17

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

Anja Lorch, Caroline Mollévi, Andrew Kramar et al. · Journal of Clinical Oncology · 2011 · 269 citations · Full text

Medicine, Oncology, Chemotherapy +15

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

Thomas Powles, Peter H. O’Donnell, Christophe Massard et al. · Journal of Clinical Oncology · 2017 · 69 citations

Medicine, Oncology, Pharmacotherapy +15

Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?

Christophe Massard, A. Plantade, Marine Gross‐Goupil et al. · Annals of Oncology · 2010 · 47 citations · Full text

Medicine, Oncology, Chemotherapy +13